Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Research output: Contribution to journalReviewResearchpeer-review

  1. Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

A wider use of L-asparaginase in the treatment of children with acute lymphoblastic leukemia has improved cure rates during recent decades and hence led to introduction of pediatric-inspired treatment protocols for adolescents and young adults. In parallel, a range of burdensome, often severe and occasionally life-threatening toxicities have become frequent, including hypersensitivity, hepatotoxicity, hypertriglyceridemia, thromboembolism, pancreatitis, and osteonecrosis. This often leads to truncation of asparaginase therapy, which at least in the pediatric population has been clearly associated with a higher risk of leukemic relapse. Many of the asparaginase induced toxicities are far more common in older patients, but since their relapse rate is still unsatisfactory, the decision to discontinue asparaginase therapy should balance the risk of toxicity with continued asparaginase therapy against the risk of relapse in the individual patient. The underlying mechanisms of most of the asparaginase induced side effects are still unclear. In this review we address the individual toxicities, known risk factors, and their clinical management.

Original languageEnglish
JournalClinical Lymphoma, Myeloma & Leukemia
Issue number11
Pages (from-to)725-733
Number of pages9
Publication statusPublished - Nov 2021

    Research areas

  • Hepatotoxicity, Hyperlipidemia, Hypersensitivity, Pancreatitis, Thromboembolism

ID: 67654363